A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia.

Trial Profile

A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2014

At a glance

  • Drugs Sapacitabine (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 13 Jan 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2009-1002).
    • 12 Dec 2011 Interim results were reported at the Annual Meeting of the American Society of Hematology (ASH).
    • 08 Nov 2011 Planned end date changed from 1 Oct 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top